Remove 2023 Remove Drugs Remove Process Chemistry
article thumbnail

Macrocyclization via Ring-Closing Metathesis in Drug Discovery & Process Chemistry

Drug Hunter

Macrocyclic molecules, containing 12 or more atoms in a ring system, are increasingly prevalent in drug discovery, with over 67 macrocyclic drugs approved so far and several notable examples of clinical success highlighted on Drug Hunter recently, including MK-0616 , repotrectinib , and pacritinib.

article thumbnail

Process Chemistry Unleashed: A 'Fit-for-Purpose' Approach to Accelerate IND Filing

Fierce BioTech

Process Chemistry Unleashed: A 'Fit-for-Purpose' Approach to Accelerate IND Filing pesurya Thu, 07/27/2023 - 11:27 Tue, 09/05/2023 - 10:00 Resource Type Webinar Qixuan Lu Duration 60 Minutes Process chemistry plays a pivotal role in various stages of the pharmaceutical R&D cycle. Click here to login.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. However, in the quest to tackle challenging disease targets with difficult drug binding sites, there is revived interest in developing this compound type to offer unique solutions.

article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. However, in the quest to tackle challenging disease targets with difficult drug binding sites, there is revived interest in developing this compound type to offer unique solutions.

article thumbnail

Welcome to new Director David Hulcoop

The Open Targets Blog

David Hulcoop, previously Strategy and Operations Director for the consortium, starts as Executive Director of Open Targets in October 2023. I then moved back to the UK to work as a process chemist at GSK, designing the manufacturing routes for small molecule drugs. This problem of target selection is a big one.